8-K: Medtronic Announces Strong Q4 and FY25 Results, Plans Diabetes Business Spin-Off

Medtronic reports a strong finish to its fiscal year with increased revenue, EPS, and announces the intent to separate its Diabetes business into a new standalone public company.

Summary

• Medtronic announced its Q4 and FY25 financial results, with Q4 revenue reaching $8.9 billion, a 3.9% increase as reported and 5.4% organic.
• Q4 GAAP diluted EPS increased by 67% to $0.82, while non-GAAP diluted EPS increased by 11% to $1.62.
• FY25 revenue reached $33.5 billion, a 3.6% increase as reported and 4.9% organic.
• FY25 GAAP diluted EPS increased by 31% to $3.61, and non-GAAP diluted EPS increased by 6% to $5.49.
• The company intends to separate its Diabetes business into a new standalone public company within 18 months, with an IPO and subsequent split-off as the preferred path.
• The dividend for Q1 FY26 was increased to $0.71 per share, implying an annual dividend of $2.84 per share, marking the 48th consecutive year of dividend increases.
• FY26 organic revenue growth is guided at approximately 5%, with reported revenue growth expected to be in the range of 4.8% to 5.1%.
• FY26 diluted non-GAAP EPS growth is expected to be approximately 4%, with a range of $5.50 to $5.60 including potential tariff impacts.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, strategic portfolio management, and a commitment to shareholder value. The planned spin-off of the Diabetes business is expected to unlock further value and enhance focus.

Positives

• Strong Q4 and FY25 revenue growth, driven by organic performance.
• Significant increase in GAAP diluted EPS for both Q4 and FY25.
• Continued dividend increases, marking 48 consecutive years.
• Strategic decision to separate the Diabetes business, expected to improve Medtronic's gross and operating margins and EPS.
• Positive clinical outcomes from studies in atrial fibrillation patients treated with the Affera family of technologies.
• FDA approval and launch of BrainSense Adaptive Deep Brain Stimulation (aDBS).

Negatives

• Foreign currency translation had a negative impact on both Q4 and FY25 non-GAAP diluted EPS.
• Medical Surgical Portfolio FY25 revenue decreased 0.1% reported.
• Neurovascular decreased mid-single digits on volume-based procurement in China and the recall of the Pipeline Vantage flow diverter.

Risks

• The separation of the Diabetes business is subject to customary conditions, including favorable market conditions and regulatory approvals.
• The company's forward-looking statements are subject to risks and uncertainties, including competitive factors, government regulation, and general economic conditions.
• Potential impacts from increased tariffs could affect FY26 diluted non-GAAP EPS.
• The company faces risks related to the development, manufacturing, marketing, and sale of medical products.

Future Outlook

Medtronic is guiding for FY26 organic revenue growth of approximately 5% and diluted non-GAAP EPS growth of approximately 4%, with a range of $5.50 to $5.60 including potential tariff impacts.

Management Comments

• 'We had a strong close to our fiscal year, and I'm excited to see the progress we are making as our growth drivers continue to build momentum,' said Geoff Martha, Medtronic chairman and chief executive officer.
• 'The underlying fundamentals of our business are strong, and they are getting stronger.
• We are now at an inflection point as we accelerate our speed of travel to higher, more profitable growth.'
• 'Our fiscal 2026 guidance reflects increasing revenue growth contribution from our key growth drivers, and increased investment to support their growth, leading to leveraged operating profit growth pre-tariffs,' said Thierry Piton, Medtronic chief financial officer.
• 'This is an exciting time to join Medtronic.
• I am energized by the opportunities for durable growth and value creation ahead of us.'

Industry Context

Medtronic's announcement reflects a broader trend in the medical technology industry of focusing on high-growth, high-margin segments and streamlining portfolios through strategic separations and acquisitions. The spin-off of the Diabetes business allows Medtronic to concentrate on its core strengths and innovation pipeline, while creating a more focused and agile Diabetes company.

Comparison to Industry Standards

• Medtronic's organic revenue growth of 4.9% for FY25 is comparable to other large-cap medical device companies, such as Johnson & Johnson's MedTech segment and Abbott, which have also reported mid-single-digit organic growth.
• The planned separation of the Diabetes business mirrors similar strategic moves by other healthcare conglomerates, such as Siemens Healthineers' spin-off from Siemens AG, to unlock value and enhance focus.
• Medtronic's dividend increase marks its 48th consecutive year, demonstrating a commitment to returning value to shareholders, a common practice among established medical device companies.

Management Changes

Stakeholder Impact

• Shareholders are expected to benefit from the increased focus and efficiency of both Medtronic and the New Diabetes Company.
• Employees of the Diabetes business will transition to the New Diabetes Company.
• Patients are expected to benefit from the increased innovation and focus on diabetes management.
• Customers (healthcare systems and physicians) will benefit from Medtronic's enhanced focus on its core strengths.

Next Steps

• Complete the separation of the Diabetes business within 18 months.
• Continue to advance innovation pipeline and product launches.
• Execute on FY26 guidance for revenue and EPS growth.
• Report FY26 first quarter results on August 19, 2025.

Key Dates

Keywords

Medtronic, financial results, revenue, EPS, Diabetes business, spin-off, dividend, organic growth, GAAP, non-GAAP